A
A. Jennifer Fischbach
Researcher at LDS Hospital
Publications - 9
Citations - 1992
A. Jennifer Fischbach is an academic researcher from LDS Hospital. The author has contributed to research in topics: Performance status & Anaplastic astrocytoma. The author has an hindex of 9, co-authored 9 publications receiving 1953 citations. Previous affiliations of A. Jennifer Fischbach include Radiation Therapy Oncology Group.
Papers
More filters
Journal ArticleDOI
Recursive Partitioning Analysis of Prognostic Factors in Three Radiation Therapy Oncology Group Malignant Glioma Trials
Walter J. Curran,Charles B. Scott,John Horton,James S. Nelson,Alan S. Weinstein,A. Jennifer Fischbach,Chu H. Chang,Marvin Rotman,Sucha O. Asbell,Robert E. Krisch,D. F. Nelson +10 more
TL;DR: In this paper, the authors used a nonparametric statistical technique to examine the associations of both pretreatment patient and tumor characteristics and treatment-related variables with survival duration for malignant glioma patients.
Journal ArticleDOI
Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06
Charles Scott,Charles W. Scarantino,Raul Urtasun,Benjamin Movsas,Christopher U Jones,Joseph R Simpson,A. Jennifer Fischbach,Walter J. Curran +7 more
TL;DR: The validity of the model is verified by the reliability of the RPA classes to define distinct groups with respect to survival, and their usefulness as historical controls for the comparison of future Phase II results is attested.
Journal ArticleDOI
Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas: Radiation therapy oncology group study 83-02
Maria Werner-Wasik,Charles B. Scott,Diana F. Nelson,Laurie E. Gaspar,Kevin J. Murray,A. Jennifer Fischbach,James S. Nelson,Alan S. Weinstein,Walter J. Curran +8 more
TL;DR: The Radiation Therapy Oncology Group (RTOG) conducted a randomized Phase I/II study of escalating doses of HF and AHF with carmustine for adults with supratentorial glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA) and primary study endpoints were overall survival and acute and chronic treatment‐related toxicity.
Journal ArticleDOI
Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials
Walter J. Curran,Charles Scott,John Horton,James S. Nelson,Alan S. Weinstein,Diane F. Nelson,A. Jennifer Fischbach,Chu H. Chang,Marvin Rotman,Sucha O. Asbell,William D. Powlis +10 more
TL;DR: Multivariate analysis demonstrated that only younger age, frontal location, and smaller tumor size correlated significantly with extended survival, and smaller tumor size and frontal location favorably influence outcome even when adjusted by age.
Journal ArticleDOI
All-trans-retinoic acid: a phase II radiation therapy oncology group study (RTOG 91-13) in patients with recurrent malignant astrocytoma
Surasak Phuphanich,Charles Scott,A. Jennifer Fischbach,A. Jennifer Fischbach,Corey Langer,W.K. Alfred Yung +5 more
TL;DR: This study suggests that this dose of singleagent all-trans-retinoic acid has modest clinical activity against recurrent malignant gliomas with tolerable side effects and a response rate of 12% and a stabilization rate 12% are lower than expected.